FRPath
View FRPs
References
Asia
Choose a country below to begin
ASEAN
- ASEAN harmonized requirements for drug registration (SIAHR)- Full JA
- Expedited Joint Assessment Procedure
Brunei Darussalam
- Abridged Route
China
- Conditional Approvals for New Drugs
- Prioritized Drug Review and Approval Pathway
- Breakthrough Therapy Designation (BTD)
- The Special Approval Pathway (SAP) for COVID-19 related products
- Priority Review
Hong Kong
- Registration of Advanced Therapy Products
Indonesia
- Path IV (new life saving drugs)
- Path V (prior approved)
Japan
- The time-limited conditional approval system for regenerative medicines
- PMDA Conditional Early Approval
- Priority Review
- PMDA Sakigake (Pioneering Drug Designation)
Malaysia
- Verification Review
- Abbreviated Review
- Priority Pathway
- Orphan Drug Route
- Conditional Registration for Pharmaceutical Products During Disaster
- Conditional Registration for New Chemical Entities and Biologics in Malaysia
Philippines
- Facilitated Registration of Applications
- Accelerated registration of WHO-prequalified products
- Orphan Drug Route
- Registration of Drug Products under Emergency Use for the Coronavirus Disease 2019 (COVID-19) (INITIAL-DEU)
- Verification Review
- Abridged Review
Singapore
- Verification - CECA Route
- GDA Verification Route
- GDA Abridged Route
- NDA Abridged Route
- NDA Verification Evaluation Route
South Korea
- Prior Review
Sri Lanka
- Fast Track Review
- Priority Review
Taiwan (Chinese Taipei)
- Priority Review
- Accelerated Approval
- Abbreviated Review
- Taiwan Orphan Drug Pathway
Thailand
- Abridged Evaluation of New Drugs
Vietnam
- Abridged Procedure
- Orphan Drug Route
Copyright © 2020-2021 FRPath.org | All Rights Reserved FRPath
®
the Erudee Foundation | An Erudee Foundation Research Project